Cytosorbents Corporation (CTSO) reports 25% Q4 revenue growth, strong margins, and updates on FDA-reviewed DrugSorb-ATR launch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback